Trek Therapeutics, PBC   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2014)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2015
NCT02593162
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

faldaprevir (2 trials)

ribavirin (virazole) (2 trials)

td-6450 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3